NANJING, China, Feb. 11 Simcere Pharmaceutical Group("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical companyspecializing in the development, manufacturing, and marketing of brandedgeneric and proprietary pharmaceuticals in China, today announced that one ofits subsidiaries, Nanjing Simcere Dongyuan Pharmaceutical Co. Ltd., hasreceived new drug registration approval from the State Food and DrugAdministration ("SFDA") to manufacture and sell Zanamivir, a neuraminidaseinhibitor inhalant used in the prevention and treatment of Influenza A andInfluenza B. Zanamivir is marketed globally by GlaxoSmithKline under the tradename Relenza.
Zanamivir is one of only two WHO approved drugs to which the new H1N1strain of influenza A has been shown to be susceptible. GlaxoSmithKlinegranted a license to Simcere in 2006 to manufacture and sell Zanamivir and itsformulations in China. Simcere is the only pharmaceutical company in mainlandChina that has such a license.
Mr. Jinsheng Ren, Chairman and Chief Executive Officer of SimcerePharmaceutical Group, commented, "We are delighted to receive SFDA approval tomanufacture and sell Zanamivir, which has proved very successful in the fightagainst the H1N1 strain of Influenza A. With our leading domesticmanufacturing facilities, well-known brand and nationwide marketing platform,Simcere is well prepared to bring this exciting drug to China."
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leadingpharmaceutical company specializing in the development, manufacturing, andmarketing of branded generic and proprietary pharmaceuticals in China. Inrecent years, Simcere has been focusing its strategy on the development ofinnovative pharmaceuticals and first-to-market generics, and has introduced aninnovative anti-cancer medication Endu, a first-to-market medication Sinofuan,and first-to-market generics such as Bicun and Anxin. Simcere manufactures andsells antibiotics, anti-cancer medication, stroke management medication andbiopharmaceutical drugs such as vaccines. Simcere concentrates its researchand development efforts on the treatment of diseases with high incidenceand/or mortality rates and for which there is a clear demand for moreeffective pharmacotherapy such as cancer, strokes, orthopaedics and infectiousdiseases. For more information about Simcere Pharmaceutical Group, pleasevisit http://www.simcere.com .For more information, please contact: Investor and Media Contacts: Email: email@example.com In Nanjing: Frank Zhao Chief Financial Officer Simcere Pharmaceutical Group Tel: +86-25-8556-6666 x8818 In Beijing: Ruirui Jiang Brunswick Group Tel: +86-10-6566-2256 In the United States: Kate Tellier Brunswick Group Tel: +1-212-333-3810 In Hong Kong: Joseph Lo Chi-Lun Brunswick Group Tel: +852-3512-5000
SOURCE Simcere Pharmaceutical Group